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Background-—Intestinal microbiota have been found to be linked to cardiovascular disease via conversion of the dietary
compounds choline and carnitine to the atherogenic metabolite TMAO (trimethylamine-N-oxide). Speciﬁcally, a vegan diet was
associated with decreased plasma TMAO levels and nearly absent TMAO production on carnitine challenge.
Methods and Results-—We performed a double-blind randomized controlled pilot study in which 20 male metabolic syndrome
patients were randomized to single lean vegan-donor or autologous fecal microbiota transplantation. At baseline and 2 weeks
thereafter, we determined the ability to produce TMAO from d6-choline and d3-carnitine (eg, labeled and unlabeled TMAO in
plasma and 24-hour urine after oral ingestion of 250 mg of both isotope-labeled precursor nutrients), and fecal samples were
collected for analysis of microbiota composition. 18F-ﬂuorodeoxyglucose positron emission tomography/computed tomography
scans of the abdominal aorta, as well as ex vivo peripheral blood mononuclear cell cytokine production assays, were
performed. At baseline, fecal microbiota composition differed signiﬁcantly between vegans and metabolic syndrome patients.
With vegan-donor fecal microbiota transplantation, intestinal microbiota composition in metabolic syndrome patients, as
monitored by global fecal microbial community structure, changed toward a vegan proﬁle in some of the patients; however, no
functional effects from vegan-donor fecal microbiota transplantation were seen on TMAO production, abdominal aortic 18F-
ﬂuorodeoxyglucose uptake, or ex vivo cytokine production from peripheral blood mononuclear cells.
Conclusions-—Single lean vegan-donor fecal microbiota transplantation in metabolic syndrome patients resulted in detectable
changes in intestinal microbiota composition but failed to elicit changes in TMAO production capacity or parameters related to
vascular inﬂammation.
Clinical Trial Registration-—URL: http://www.trialregister.nl. Unique identiﬁer: NTR 4338. ( J Am Heart Assoc. 2018;7:e008342.
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I ntestinal microbiota are increasingly recognized as a factorunderlying the pathobiology of several disease states,
including cardiovascular disease (CVD). The intestinal micro-
biota composition in patients with symptomatic CVD differs
signiﬁcantly from that in healthy controls.1,2 Moreover, DNA
from intestinal microbiota has been recovered from human
atherosclerotic plaques, suggesting a potentially contributory
role of gut microbiota to atherosclerosis.1 Several potential
mechanisms have linked altered intestinal microbiota com-
position and function to CVD. First, traditional cardiovascular
risk factors, such as insulin resistance3 and, more recently,
dyslipidemia,4 have been associated with altered intestinal
microbiota composition. Because fecal microbiota transplan-
tation (FMT) from lean to obese insulin-resistant individuals
improved the metabolic proﬁle in the latter group,5 these
ﬁndings suggest a causal role for intestinal microbiota in CVD.
Second, intestinal microbiota composition affects peripheral
blood mononuclear cell (PBMC) production capacity,6 which
was linked to increased vascular inﬂammation and atheroscle-
rosis.7
The recent discovery of TMAO (trimethylamine-N-oxide), a
novel intestinal microbiota–related metabolite involved in
atherosclerosis, provides a more direct link between intestinal
microbiota and CVD. Intestinal bacteria are capable of producing
TMA (trimethylamine) from endogenous and dietary phos-
phatidylcholine, as well as from carnitine, a nutrient mainly
present in animal-derived food products. TMA is subsequently
oxidized in the liver to TMAO in a reaction catalyzed by host
hepatic ﬂavin monooxygenases, particularly ﬂavin monooxyge-
nase 3.8 Plasma TMAO levels were found to be related to
incident CVD in large prospective observational studies, and
animal-model studies suggest a potentially causal role for TMAO
in atherogenesis.9–11 In support, TMAO increased atheroscle-
rotic lesion size in mice.9 Interestingly, individuals on a vegan
diet are known to have an altered intestinal microbiota
composition,12,13 which might partly explain the diminished
capacity to produce TMAO11 and the tendency toward
decreased cardiovascular risk in vegans compared with
omnivores.14 In contrast, omnivorous metabolic syndrome
patients are known to have a 2-fold increased cardiovascular
risk15 as well as increased TMAO production.16 Plasma TMAO
level in metabolic syndrome patients has been found to be an
independent risk factor for CVD-associated mortality,17 and
TMAO production and associated atherosclerotic risk were
transmittable by FMT in mice.18 In conjunction with the fact that
inhibition of TMA lyase, a bacterial enzyme responsible for
conversion of choline and carnitine to TMA, reduced TMAO levels
and thus atherosclerosis inmice,19 this underscores theneed for
assessing a potentially causal role of intestinal microbiota in
human TMAO production and, eventually, cardiovascular risk.
In the present double-blind randomized controlled pilot
study, we investigated whether single lean vegan-donor FMT
in omnivorous metabolic syndrome patients affects the
intestinal microbiota composition and, subsequently, the
conversion of both choline and carnitine to TMA and TMAO,
compared with autologous (own feces) FMT. Moreover, we
assessed the effect of vegan-donor FMT on vascular inﬂam-
matory tone by measuring aortic wall vascular inﬂammation,
as assessed using 18F-ﬂuorodeoxyglucose (18F-FDG) uptake
positron emission tomography/computed tomography (PET/
CT) scanning, which is reported to be increased in metabolic
syndrome patients.20 We also examined ex vivo cytokine
production by PBMCs.21
Methods
The data, analytic methods, and study materials are available
to other researchers for purposes of reproducing the results
or replicating the procedure. The data are available from the
corresponding author on reasonable request.
Clinical Perspective
What Is New?
• Lean vegans have different microbiota composition and
lower capacity to produce TMAO (trimethylamine-N-oxide)
compared with obese omnivores.
• Single lean vegan-donor fecal microbiota transplantation in
obese male patients with metabolic syndrome resulted in
changes in intestinal microbiota composition, but this did
not translate into altered carnitine- or choline-to-TMAO
conversion, nor did it affect markers of arterial wall
inﬂammation.
• This lack of effect might be explained by the residual
capacity to convert carnitine to TMAO in vegans and by
limited baseline differences in intestinal microbiota compo-
sition between vegans and omnivores in conjunction with a
relatively short follow-up period of 2 weeks.
What Are the Clinical Implications?
• Our data oppose the previously stated hypothesis that the
intestinal microbiota in vegans is incapable of carnitine-to-
TMAO conversion.
• Nevertheless, this small pilot study was the ﬁrst to directly
assess the potential causal link among intestinal microbiota,
TMAO metabolism, and arterial wall inﬂammation in
humans.
• Larger and better powered intervention studies with longer
follow-up periods are necessary to further unravel the link
between vegan microbiota and atherosclerotic burden via
TMAO metabolism.
• Establishing the presence of such a link would encourage
new interventions to alleviate cardiovascular risk by directly
targeting the intestinal microbiota.
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Study Design
In this double-blinded, randomized, controlled, pilot study, we
compared the effect of FMT in 20 obese metabolic syndrome
patients using either lean, vegan-donor feces (vegan-donor
FMT, n=10) or feces from the patients themselves (autologous
FMT, n=10). Participants were randomized using a 1:1
allocation ratio. At baseline and 2 weeks after FMT, an oral
stable isotope–labeled choline and carnitine challenge test
(CCCT) was performed, combined with 18F-FDG PET/CT
scanning of the abdominal aorta. We also collected fasting
blood samples for ex vivo cytokine production assays, as well
as plasma, 24-hour urine, and fecal samples. Vegan donors
(n=9) underwent all baseline experiments including the oral
stable isotope–labeled carnitine challenge test.
All study procedures were performed at the Academic
Medical Center (Amsterdam, the Netherlands). The research
protocol was approved by the investigational review board of
the Academic Medical Center and executed according to
current Good Clinical Practice guidelines (Declaration of
Helsinki) and applicable national law. Written informed
consent was obtained from all participants before any study
procedure was performed. The study was registered in the
Dutch Trial Registry (registration number NTR 4338).
Study Population
Male obese participants of West European genetic back-
ground were recruited by newspaper advertisements and
screened for characteristics of the metabolic syndrome. We
included male adults (aged 21–69 years) who were obese
(body mass index ≥30) but otherwise healthy and who
fulﬁlled the criteria of the metabolic syndrome (fasting
glucose ≥5.6 mmol/L and ≥2 of the following criteria:
triglyceride levels ≥1.7 mmol/L; high-density lipoprotein
cholesterol <1.0 mmol/L; blood pressure ≥130/85 mm Hg;
waist circumference ≥102 cm), without a history of CVD,
cholecystectomy, or immunodeﬁciency and without the use
of any medication (including antibiotics and proton pump
inhibitors within the preceding 3 months). Participants had
to adhere to an omnivorous diet without using any type of
(food) supplements, speciﬁcally choline- and/or carnitine-
enriched products.
Healthy, lean (body mass index 20–25), adult (aged 21–
69 years) men of West European genetic backgrounds who
adhered to a vegan diet were also recruited via newspaper
advertisements to serve as feces donors. The detailed
screening procedure for feces donors in our hospital has
been published previously.22 In short, donors were initially
screened using an extensive questionnaire addressing risk
factors for potentially transmittable diseases. Subsequently,
plasma and feces were screened for potential pathogenic
parasites, bacteria, and viruses. In line with our recent
publication,23 donors were screened for the presence of
(antibodies to) human immunodeﬁciency virus; human T-
lymphotropic virus; hepatitis A, B, and C; cytomegalovirus;
Epstein–Barr virus; strongyloides; amoebiasis, and lues.
Presence of infection resulted in exclusion, although previ-
ous, nonactive infections with Epstein–Barr virus and
cytomegalovirus were allowed. Donors were also excluded
if screening of their feces revealed the presence of
pathogenic parasites (eg, blastocystis hominis, dientamoeba
fragilis, giardia lamblia), bacteria (Shigella, Campylobacter,
Yersinia, Salmonella, enteropathogenic Escherichia coli, and
Clostridium difﬁcile) or viruses (noro-, rota-, astro-, adeno
(40/41/52)-, entero-, parecho-, and sapovirus). As an extra
safety procedure, donors were again screened for contraindi-
cations directly before every feces donation by using a
second questionnaire focusing on newly developed con-
traindications to donorship. In addition, both metabolic
syndrome patients and vegan donors had to adhere to their
own diet during their participation in the study. To this end,
participants recorded their diet in the 7 days preceding the
CCCT via an online nutritional diary (http://mijn.voedingsce
ntrum.nl/nl/).
Study Procedures
Choline and carnitine challenge test
After an overnight fast and plasma collection at time point 0
(t=0), participants orally ingested a capsule containing
250 mg of stable isotope–labeled d6-choline
10 together with
a capsule containing 250 mg of stable isotope–labeled d3-
carnitine.11 Two hours thereafter, a standardized vegan meal,
consisting of 2 slices of vegan bread with vegan jam, was
given to all participants. Urine was collected in the 24 hours
following stable isotope ingestion, and plasma was collected
2, 4, 6, and 24 hours after stable isotope ingestion. There
were no dietary restrictions from 6 hours after start of the
CCCT. In plasma (venous EDTA) and urine samples, 4 volumes
of methanol containing 10 lmol/L d9-TMA and d9-TMAO
were added to precipitate the protein. The supernatant was
collected after centrifugation at 20 000g, 4°C, during 10 min-
utes and used for liquid chromatography/tandem mass
spectrometry quantitation, as described previously.24 The
distinct isotopologue (d3-/d6-) TMA and (d3-/d6-) TMAO and
their respective internal standards were analyzed using high-
performance liquid chromatography with online electrospray
ionization tandem mass spectrometry utilizing positive MRM
mode with characteristic parent-to-daughter ion transitions as
follows: m/z 63?47, 66?47, 69?49, 79?62, 82?65, and
85?68 for d3-TMA, d6-TMA, d9-TMA, d3-TMAO, d6-TMAO, and
d9-TMAO, respectively. This method has a high degree of
precision with total coefﬁcient of variance <7.0% for TMAO
and TMA and their respective isotopologues.24
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PBMC cytokine production capacity
PBMCs were isolated from venous EDTA blood, as obtained at
the CCCT (t=0), using Ficoll-Paque density gradient centrifu-
gation. The cells were subsequently cultured for 24 hours in
the presence of 10 ng/mL E coli lipopolysaccharide (E coli
serotype 055:B5), 19106 colony-forming units (CFU)/mL
heat killed E. coli, 19106 CFU/mL Bacteroides fragilis (cul-
tured in house), or 10 lg/mL oxidized low-density lipoprotein
(isolated and oxidized, as described previously).25 IL-1b
(interleukin 1b) and TNF-a (tumor necrosis factor a) concen-
trations in the supernatant were determined with commer-
cially available ELISA kits from R&D Systems, and the ELISA
kits for IL-6 and IL-10 were purchased from Sanquin, as
published previously.6
Measurement of aortic wall inﬂammation by 18F-FDG
PET/CT scan
On the day following the CCCT, a PET/CT scan (Philips
Gemini; Philips) of the abdominal aortic wall was performed
90 minutes after the infusion of 18F-FDG. The FDG uptake
was assessed by drawing a region of interest of 5
subsequent slices of the abdominal aorta, starting at the
most cranial part of the liver and moving caudally. The mean
of the maximized standardized FDG uptake value (maximal
pixel activity per region of interest) of the 5 slices was
assessed by a blinded reader. To correct for blood pool
activity, a target-to-background value was used by dividing the
mean maximized standardized FDG uptake value by the mean
background activity in 5 regions of interest in the lumen of the
adjacent inferior vena cava.26 Reproducibility studies from our
institution have been published recently and show high
interscan, interreader, and intrareader agreement with an
intraclass correlation coefﬁcient of >0.95.27
Fecal microbiota transplantation
On the day of treatment, both the metabolic syndrome
patients and the vegan donors provided the investigators with
a fresh morning fecal sample, stored at 4°C. Patients
thereafter received bowel lavage with 2 L of a macrogol
solution (Klean-Prep; Norgine Pharmaceuticals) via a naso-
duodenal tube. After bowel lavage and based on randomiza-
tion, feces from either the donor (vegan-donor FMT) or the
patient (autologous FMT) was used to prepare the infusate.
The complete stool production was diluted with 500 mL of
sterile saline (0.9%) and subsequently stirred and ﬁltered,
resulting in a 500-mL homogenized solution. Within 6 hours
of collection of the fecal material, the solution was infused
through the nasoduodenal tube. In contrast to other clinics,23
we prefer to use duodenal infusion for FMT administration
rather than infusion via colonoscopy because of the potential
role of the small intestine in metabolism, as well as logistical
reasons and the low complication rate at our institution.
Analysis of fecal microbiota composition
DNA from fecal samples was isolated using repeated bead
beating, described in detail elsewhere.28 Concentration and
purity were assessed with a Nanodrop 1000 spectropho-
tometer (Thermo Fisher Scientiﬁc). The microbial composition
was determined using a previously described and bench-
marked custom-made phylogenetic microarray, the Human
Intestinal Tract Chip (HITChip).29 This is a custom-made
Agilent microarray containing 5500 speciﬁc oligonucleotide
probes. In short, the full-length 16S rRNA gene was ampliﬁed,
transcribed into RNA, labeled with the ﬂuorescent dyes Cy3
and Cy5, and hybridized to the array. Each sample was
hybridized twice with a Pearson correlation of >0.98 between
replicates to ensure that reproducibility and raw signal
intensities were normalized, as described previously.30
The HITChip microarray can detect 1033 species-like
bacterial phylotypes (level 3, >98% 16S rRNA gene sequence
similarity) that represent the majority of the microbial
diversity in the human intestine. These were summarized to
130 genuslike phylogenetic groups (level 2, >90% 16S rRNA
gene sequence similarity), referred to as species and relatives.
Diversity of the microbiota was quantiﬁed based on nonlog-
arithmized HITChip oligo-level signals by the Shannon index
using the “vegan” package (R version 2013, Community
ecology package). Probes were counted in each sample to
measure richness by using an 80% quantile threshold for
detection.
Sample size calculation and end points
In line with our previous proof-of-concept study on the effects
of lean omnivorous donor FMT on insulin sensitivity in men
with the metabolic syndrome5 and based on a murine study
on FMT and TMAO,18 we aimed to detect a 20% reduction in
postprandial incremental area under the curve (AUC) of
plasma TMAO levels (from d6-labeled choline and d3-labeled
carnitine) with vegan donor FMT with an SD of 15%, whereas a
5% difference was expected with autologous FMT. Using an
unpaired 2-sided t test (with a=0.025 and 80% power), the
estimated sample size needed was 18 metabolic syndrome
patients for each treatment arm. Estimating dropout of 10%,
we aimed to include 20 metabolic syndrome patients per arm.
Moreover, we aimed to include 10 vegan FMT donors.
Between October 2013 and November 2015, a total of
2910 men with metabolic syndrome and 9 male vegan
donors were included (1 donor was used for 2 vegan-donor
FMTs). A futility analysis was performed based on postpran-
dial TMAO changes and showed a conditional power of 11%,
suggesting that even with 20 participants per treatment arm,
we would not achieve signiﬁcant differences after treatment.
We therefore decided to prematurely terminate the study. The
primary end point of the study was the change in incremental
DOI: 10.1161/JAHA.117.008342 Journal of the American Heart Association 4
Vegan FMT Does Not Change TMAO Production Smits et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 30, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
AUC of postprandial TMAO from d6-labeled choline and d3-
labeled carnitine as well as changes in intestinal microbiota
composition 2 weeks after vegan-donor FMT. The secondary
end points were effects of vegan-donor FMT on vessel wall
inﬂammation, as assessed by 18F-FDG PET/CT scan, as well
as ex vivo PBMC-derived cytokine production.
Randomization and blinding
An independent physician used computerized block random-
ization, using blocks of 4 patients, to ensure balanced
inclusion rates in case inclusion targets were not reached.
This did not incorporate stratiﬁcation to ensure equal
demographic and metabolic parameters between both treat-
ment groups. Treatment days were planned after ascertaining
availability of a recipient and donor on the same day.
Allocation of treatment was determined by chronologically
following the randomization ﬁle. At the day of FMT, the
independent physician revealed the intended treatment to
the research assistant, who provided the trial physician with
the fecal material from either the assigned donor or metabolic
syndrome patient. The study participants (eg, vegan donors
and metabolic syndrome patients) and all trial physicians
(including all authors) were blinded for the treatment until
completion of the trial.
Statistical Analyses
All data are presented as mean (SD) or median (interquartile
range [IQR]), depending on the distribution of the data.
Differences between vegan donors and metabolic syndrome
patients were tested using a Student t test for normally
distributed data and a Mann–Whitney U test for nonnormal
distributed data. The effect of FMT on d3- and d6-TMA and -
TMAO plasma and urine markers as well as 18F-FDG uptake
was tested using a paired t test or Wilcoxon signed rank test,
depending on the data distribution. A P value <0.05 was
considered signiﬁcant. The microbiota data were corrected for
multiple testing, as described below.
Fecal microbiota that allowed accurate discrimination
among groups of patients (vegan-donor versus autologous
FMT) were selected by means of the elastic net algorithm.31
The elastic net method is applicable to structured and high-
dimensional data. It is a regularized method that combines the
advantages of 2 techniques: LASSO and ridge regression as
previously published by our group.32 This combination allows
for the selection of the most important microbiota while
taking the correlation (“grouping effect”) among them into
account. We used an adapted version of the elastic net algo-
rithm (with Hinge loss function). Although the microbiota
identiﬁed by the elastic net algorithm frequently lead to
statistically signiﬁcant results, they can also be unstable. In
our approach, we addressed this problem via a stability-
selection procedure33 coupled with model selection. Bacterial
stability is reﬂected in the frequency that a particular
bacterium was identiﬁed in multiple simulations on a reran-
domized data set. This measure is especially relevant for
small- to medium-sized data collections, as in this study, for
which the number of patients was limited. To avoid overﬁtting,
we used a 10-fold stratiﬁed cross-validation procedure over
the training partition of the data (80%), and the remaining 20%
were used as the testing data set. Stability selection was
performed by randomly subsampling 80% of the data 100
times. During the stability-selection procedure, all features
having a nonzero weight coefﬁcient were counted. These
counts were normalized and converted to stability coefﬁcients
having a value between 1.0 (for the feature that was always
selected) and 0.0 for the feature that was never selected. We
used Python (version 2.7.8, packages Numpy and Scipy) for
implementing the elastic net model and R version 3.1.2 for
visualization.
A randomization test was conducted to evaluate the
statistical validity of the results obtained via the elastic
net algorithm. We followed the procedure in which the
outcome variable (vegan-donor versus autologous FMT) was
randomly reshufﬂed while the corresponding microbiota
proﬁles were kept intact. This was repeated up to 100 times
and receiver operating characteristic area under the curve
scores were computed each time. To study the dynamics of
the microbiota, we computed the relative change for each
individual patient over time. To assess the amount of change
in intestinal microbiota composition per patient per consec-
utive interval, we computed the magnitude of change using L2
norm. To visualize and study correlations among the patients
at different time points, we used redundancy analysis.34
Redundancy analysis can be considered a constrained version
of principal components analysis, in which the canonical axes
are built from linear combinations of the response variables.
Redundancy analysis extends multiple linear regression by
allowing regression of multiple response variables on multiple
explanatory variables.
Results
In total, we included 20 metabolic syndrome patients and 9
vegan feces donors. None of the included participants was
prematurely lost to follow-up after randomization. However,
technical failure prevented analyses of PET/CT scans for 3
metabolic syndrome patients (1 baseline scan before vegan-
donor FMT, 1 baseline scan before autologous FMT, and 1
posttreatment scan after vegan-donor FMT) and 1 vegan
donor. In addition, no incremental AUC for plasma d3-TMAO
was available for 2 metabolic syndrome patients because of
missing samples at time point 24 hours (t=24) (1 before
vegan-donor FMT, 1 before autologous FMT). Unlabeled
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plasma TMAO and 24-hour urine TMA, TMAO, d3-TMA, and d3-
TMAO excretion was available for all patients for baseline and
after FMT.
Metabolic syndrome patients were older (55.0 versus
33.4 years, P=0.002), had higher body mass index (33.9
versus 22.9, P<0.001) and had increased cardiovascular risk
proﬁles compared with vegan donors, as a result of the study
design (Table). Cardiovascular risk factors were similar at
baseline between metabolic syndrome patients randomized to
treatment with autologous or vegan-donor FMT. No serious
adverse events were reported in either study group. We also
observed no changes in safety laboratory parameters (eg,
hematology, renal function, liver chemistry) on vegan-donor
FMT (Table S1), and vegan-donor FMT did not affect vital signs
(eg, pulse rate, blood pressure; data not shown). In line,
dietary intake was not affected by either vegan or autologous
FMT (Tables S2 and S3). In the autologous FMT group, some
baseline parameters signiﬁcantly decreased with treatment
(eg, hemoglobin, alanine aminotransferase, cholesterol,
triglycerides) but remained within the normal range through-
out follow-up.
Baseline Fecal Microbiota Composition and TMAO
Metabolism in Metabolic Syndrome and Vegan
Participants
We observed a nonsigniﬁcant trend toward decreased fecal
microbial diversity in vegans versus metabolic syndrome
patients (Shannon index: 5.9 [IQR: 5.8–6.0] versus 6.0 [IQR:
5.9–6.1], P=0.08; Figure 1A), although the variation within the
metabolic syndrome group was rather large and the absolute
difference small. Redundancy analysis showed a distinction in
fecal microbiota composition between the vegan donors and
the metabolic syndrome patients (Figure 1B). Among others,
bacteria related to Anaerostipes caccae and Lachnobacterium
were associated with a vegan diet, whereas several groups
belonging to the Clostridium genus were related to metabolic
syndrome patients (Figure 1C).
With respect to TMAO production, fasting plasma con-
centrations of TMAO (3.7 lmol/L [IQR: 2.7–4.9 lmol/L]
versus 2.8 lmol/L [IQR: 1.9–3.4 lmol/L], P=0.13; Fig-
ure 2A) did not differ signiﬁcantly between metabolic
syndrome patients and vegan donors. However, 24-hour
urinary excretion of TMAO was signiﬁcantly higher in
metabolic syndrome patients versus vegan donors (529
lmol [IQR: 239–1407 lmol] versus 178 lmol [IQR: 98–338
lmol], P=0.03), whereas 24-hour urinary TMA excretion was
not signiﬁcantly different between both groups at baseline
(10.3 lmol [IQR: 3.9–23.9 lmol] versus 7.6 lmol [IQR: 3.1–
13.6 lmol], P=0.35).
To further study the capacity to convert choline and
carnitine to TMA and TMAO, a d3-carnitine/d-choline chal-
lenge test was performed. After oral administration of d3-
carnitine, a similar pattern was observed compared with
unlabeled TMAO. Although not signiﬁcant, postprandial
plasma appearance of d3-TMAO was higher in metabolic
syndrome patients than vegans (AUC [in lmol/L per
24 hours]: 114 [IQR: 68–182] versus 53 [IQR: 0–155],
Table. Baseline Characteristics
Metabolic Syndrome Patients,
All (n=20) Vegan Donors (n=9) P Value
Metabolic Syndrome Patients,
Autologous FMT (n=10)
Metabolic Syndrome Patients,
Vegan-Donor FMT (n=10) P Value
Age, y 55.08.2 33.414.8 0.002 57.78.5 52.37.4 0.15
BMI, kg/m2 33.93.8 22.91.7 <0.001 33.84.0 33.93.9 0.94
Pulse, bpm 65.912.5 70.79.9 0.32 67.813.2 63.912.2 0.50
SBP, mm Hg 150.212.3 130.66.2 <0.001 152.212.5 148.212.4 0.48
DBP, mm Hg 93.19.0 78.96.6 0.001 93.38.3 92.810.1 0.91
Glucose, mmol/L 6.00.8 5.10.3 <0.001 6.180.9 5.80.5 0.25
Insulin, miU/L 126.155.3 50.931.2 0.001 107.745.5 144.560.3 0.14
HbA1C, mmol/mol 37.84.4 34.03.4 0.03 38.73.6 36.95.1 0.37
Cholesterol, mmol/L 5.30.8 4.11.2 0.02 5.30.8 5.30.9 0.90
HDL-C, mmol/L 1.10.2 1.30.3 0.28 1.20.2 1.10.2 0.74
LDL-C, mmol/L 3.31.0 2.51.0 0.1 3.11.3 3.50.7 0.37
Triglycerides, mmol/L 1.30 (1.05–1.53) 0.82 (0.53–0.90) 0.006 1.30 (1.06–1.57) 1.27 (1.01–1.56) 0.82
CRP, mg/mL 1.50 (0.88–4.38) 0.50 (0.40–0.80) 0.005 1.90 (1.15–4.50) 1.45 (0.80–4.25) 0.65
Data are depicted as meanSD or median (interquartile range), depending on their distribution. P<0.05 was considered signiﬁcant. BMI indicates body mass index; CRP, C-reactive protein;
DBP, diastolic blood pressure; FMT, fecal microbiota transplantation; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
SBP, systolic blood pressure.
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P=0.12), and urinary excretion of both d3-TMA (AUC [in lmol/
L per 24 hours]: 3.7 [IQR: 1.2–11.1] versus 0.9 [IQR: 0–1.4],
P=0.006) and d3-TMAO (AUC [in lmol/L per 24 hours]: 562
[IQR: 225–793] versus 54 [IQR: 0–224], P=0.002) was
signiﬁcantly increased in metabolic syndrome patients versus
vegan donors (Figure 2B). In line, plasma appearance of d3-
carnitine was signiﬁcantly higher in vegans compared with
metabolic syndrome patients. Remarkably, d6-labeled choline
—and, consequently, d6-TMA and d6-TMAO in plasma and in
urine—was almost absent after oral d6-choline administration
(Figure S1) in both metabolic syndrome patients and vegans,
with no baseline difference between groups.
Figure 1. Fecal microbiota diversity and composition in metabolic syndrome patients vs lean vegan
FMT donors. A, Baseline fecal microbiota diversity of lean vegan FMT donors (Vegan) and obese
omnivorous metabolic syndrome patients (MetS), expressed as Shannon index. Data are depicted as
box-and-whisker plots. P<0.05 was considered signiﬁcant. B, RDA plot showing baseline fecal
microbiota composition of lean vegan FMT donors and obese omnivorous metabolic syndrome
patients. Ellipse curves represent the spread and distribution of the participants for both groups in 2-
dimensional RDA subspace. C, PCA biplot depicting 10 individual fecal microbiota genera that
differentiated between lean vegan FMT donors and obese omnivorous metabolic syndrome patients
at baseline. Both individual microbiota data and grouped microbiota data are shown (small or large
symbols). Ellipse curves represent the spread and distribution of the participants for both groups in 2-
dimensional PCA subspace. Dim indicates dimension; FMT, fecal microbiota transplantation; PCA,
principal components analysis; RDA, redundancy analysis.
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Fecal Microbiota Composition and TMAO
Metabolism With FMT
We found no changes in fecal microbiota diversity (Shannon
index) 2 weeks after either vegan donor FMT (from 6.0 [IQR:
5.9–6.1] to 6.1 [IQR: 5.9–6.2], P=0.260) or autologous FMT
(from 6.0 [IQR: 5.9–6.0] to 6.0 [IQR: 5.7–6.1], P=0.721;
Figure 3A), However, vegan-donor FMT did affect intestinal
microbiota composition in metabolic syndrome patients, with
changes toward a more veganlike proﬁle in some, but not all,
patients (Figure 3B). Compared with autologous FMT,
changes in fecal microbiota abundance with vegan FMT were
seen in, among others, several groups belonging to the
Lachnospiraceae, including bacteria related to Bryantella
Fasting plasma TMAO
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Figure 2. Unlabeled plasma and urine TMA/TMAO- and d3-carnitine-derived plasma and urine metabolites: metabolic syndrome patients vs
lean veganFMTdonors, and theeffect of lean vegandonorFMT.A throughC,Unlabeledplasmaandurine TMA/TMAOdata comparing lean vegan
FMT donors and obesemetabolic syndrome subjects and depicting changes after either autologous or lean vegan-donor FMT. Graph (A) shows
fastingplasmaTMAOdata,whereasGraphs (BandC)showurinaryexcretionofTMA/TMAOduring24 hoursaftercarnitineandcholinechallenge.
The d3-labeled carnitine data are shown in Graphs (D through G), includingmetabolites TMA/TMAO in plasma and urine. Again, lean vegan FMT
donorsarecomparedwithobesemetabolic syndromesubjects, andchangesafter either autologousor leanvegan-donorFMTareshown.Plasma
data represent iAUCs at 24 hours after carnitine ingestion (Graphs D and E), whereas urinary data comprise total urinary excretion during
24 hours after carnitine ingestion (Graphs F andG). Data are presented as box-and-whisker plots. P<0.05was considered signiﬁcant. Auto FMT
indicates autologous FMT; Donor FMT, lean vegan-donor FMT; FMT, fecal microbiota transplantation; iAUC, incremental area under the curve;
MetS, obese omnivorous metabolic syndrome patients; t=0/2w, time point 0/2 weeks; TMA, trimethylamine; TMAO, trimethylamine-N-oxide;
Vegans, lean vegan fecal microbiota transplantation donors.
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formatexigens and Megamonas hypermegale as well as
L bovis. In contrast, autologous FMT resulted in minor shifts
in microbiota composition and was primarily associated with
changes in the abundance of bacteria related to Alcaligenes
faecalis and Akkermansia (Figure 3C). With respect to TMAO,
vegan-donor FMT did not affect fasting plasma TMAO levels or
Figure 3. The effect of lean vegan-donor FMT in fecal microbiota diversity and composition. A, Changes in
fecal microbiota diversity 2 weeks after lean vegan-donor or autologous FMT in obese metabolic syndrome
patients, expressed as Shannon index. Data are depicted as box-and-whisker plots. P<0.05 was considered
signiﬁcant. B, RDA plot showing the changes in fecal microbiota composition in obese metabolic syndrome
patients 2 weeks after either lean vegan-donor or autologous FMT. C, Spider plot depicting individual fecal
microbiota genera that showed different changes in abundance in metabolic syndrome patients after either
lean vegan-donor or autologous FMT. The axis of the spider plot reﬂects the amount of change (L2 norm) of
the bacterial species on autologous (green) or lean vegan-donor (red) FMT. Auto FMT indicates autologous
fecal microbiota transplantation; Donor FMT, lean vegan donor fecal microbiota transplantation; FMT, fecal
microbiota transplantation; Placebo, autologous fecal microbiota transplantation; RDA, redundancy
analysis; t=0/2w, time point 0/2 weeks.
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24-hour urinary excretion of labeled and unlabeled TMA or
TMAO (Figure 2 and 2B, Figure S1). Although autologous FMT
did not inﬂuence plasma TMAO levels, and despite the large
variation, it did result in a signiﬁcant increase in urinary
excretion of d3-TMAO (from 562 [IQR: 200–625] to 683 [IQR:
434–933] lmol/24 hours, P=0.03).
18F-FDG PET/CT Scan on FMT
To study the effect of vegan-donor FMT on vascular inﬂam-
mation, 18F-FDG PET/CT scans of the abdominal aortic wall
were performed at baseline and 2 weeks after FMT. FDG
uptake in the aortic wall at baseline was not signiﬁcantly
different between metabolic syndrome patients and vegan
donors (maximized target to background: 3.250.8 versus
2.830.9, P=0.27; Figure 4). Neither vegan-donor FMT nor
autologous FMT altered aortic wall FDG uptake (Figure 4).
Baseline and posttreatment maximized target-to-background
values were, respectively, 3.491.1 and 3.430.9 (P=0.90)
in the vegan donor FMT group and 3.150.5 and 3.591.1
(P=0.28) for the autologous FMT group.
FMT Effects on Cytokine Production Capacity
Before and 2 weeks after FMT, PBMCs were isolated from
whole blood and ex vivo stimulated with different stimuli to
measure cytokine production (IL-1b, IL-6, IL-10, TNF-a).
Oxidized low-density lipoprotein production differed between
vegans and metabolic syndrome patients on 3 of 4 stimuli, but
other cytokines were similar at baseline (Figure S2). More-
over, autologous FMT resulted in increased IL-10 and IL-1b
production after Bacteroides stimulation, whereas we did not
observe any treatment-induced changes within the vegan-
donor FMT group.
Discussion
In the present double-blind, randomized, controlled, pilot
study, we show that lean vegan donor FMT in obese metabolic
syndrome patients results in altered fecal microbiota compo-
sition. Unexpectedly, these alterations do not translate into
signiﬁcant effects on choline- or carnitine-to-TMA or -TMAO
conversion. In line, no effect of vegan donor FMT was seen on
surrogate markers of cardiovascular risk including vascular
inﬂammation (aortic 18F-FDG uptake assessed by PET/CT)
and cytokine production capacity by PBMCs. These data
showed that in the time window of 2 weeks, the therapeutic
effect of a single vegan-donor FMT was not sufﬁcient to alter
systemic TMAO levels in obese patients with increased
cardiovascular risk due to metabolic syndrome.
Underscoring previous observations, our data conﬁrmed that
only limited baseline differences exist in fecal microbiota
diversity between omnivores and vegans.12,13 In vegans, we
found increased relative abundance of fecal Lachnospiraceae,
including butyrate-producing bacteria related to L bovis and
Anaerostipes,9,13,35,36 whereas metabolic syndrome patients
were enriched inClostridiales, which have been associated with
TMA production.11 In support of a previous publication,
metabolic syndrome patients are characterized by an increased
capacity to convert carnitine to TMA and, subsequently,
TMAO.11 Although it remains to be proven in larger cohorts, a
recent meta-analysis by Heianza et al37 suggests that higher
conversionof carnitine toTMAandTMAOmay result in a1.4-fold
higher risk of CVD. Meanwhile, the similarity in unlabeled TMA
excretionsuggestsadifference inhepaticﬂavinmonooxygenase
activity between metabolic syndrome patients and vegan
donors. Indeed, altered hepatic ﬂavinmonooxygenase has been
linked to insulin resistance in animalmodels.38 In contrast to the
near absence of d3-TMAO production in the study by Koeth
et al,11 the vegans inour studywere capable of somecapacity to
convert d3-carnitine to TMAO, as demonstrated by the appear-
ance of d3-TMAO in plasma and urine after d3-carnitine
challenge. This difference might reﬂect the stricter deﬁnition
Arterial wall inflammation
Me
tS
Ve
ga
ns
Au
to 
FM
T t
=0
Au
to 
FM
T t
=2
w
Do
no
r F
MT
 t=
0
Do
no
r F
MT
 t=
2w
0
1
2
3
4
5 P=0.27 P=0.28 P=0.90)xa
M
R
BT (
at ro al ani
modb
A
Figure 4. 18F-FDG PET/CT results of lean vegan
donors vs obese metabolic syndrome patients and
posttreatment changes. Shown are PET/CT results
comparing obese metabolic syndrome patients with
lean vegan FMT donors at baseline and treatment-
inducedchangeaftereither autologousor leanvegan-
donor FMT. Data are depicted as means with SDs.
P<0.05 was considered signiﬁcant. Auto FMT indi-
cates autologous fecal microbiota transplantation;
Donor FMT, lean vegan donor fecal microbiota
transplantation; FDG, ﬂuorodeoxyglucose; MetS,
obese omnivorous metabolic syndrome subjects;
PET/CT, positron emission tomography/computed
tomography; t=0/2w, time point 0/2 weeks; TBR
Max, maximum target-to-background ratio; Vegans,
lean vegan fecal microbiota transplantation donors.
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of a vegan diet used in the studies by Koeth et al, which required
>1 preceding year of using no animal products in the diet. The
near absence of both d6-choline and d6-TMA and -TMAO in
plasma and urine is remarkable compared with the d3-TMAO
concentrationswithin this study andprevious reports on labeled
choline metabolism in humans.10 It should be noted that in
the study by Tang et al,10 heavy isotope–labeled phos-
phatidylcholine and not choline was used. The in vitro
stability of the d6-choline compound was tested and shown
to be very stable (data not shown); it thus appears likely
that the free d6-choline, despite being provided at a greater
molar level than isotope–labeled phosphatidylcholine previ-
ously, was almost not absorbed by the (small) intestine,
limiting TMA and subsequent (hepatic) TMAO production.
Unfortunately, we did not obtain post-CCCT fecal samples
to determine fecal excretion of d6-labeled choline to
support this hypothesis.
TwoweeksaftervegandonorFMT, fecalsamplesofmetabolic
syndrome patients were signiﬁcantly enriched in short-chain
fatty acid producers B formatexigens and relatives39 and
M hypermegale and relatives,40 the latter of which is known as
a non–TMA-producing genus.41 In contrast, autologous FMT
affected the relative abundance of bacterial genera related to
A faecalis and Akkermansia, with the latter related to beneﬁcial
metabolic health.42 Although themechanism is unclear, it might
be that the aerobic treatment of autologous feces has selected
the oxygen-tolerant Akkermansia43 and A faecalis.44 These
bacterial strainsmay subsequently occupy the niche in the fecal
microbiota that was created by eradication of other anaerobic
species. Despite these changes in intestinal microbiota compo-
sition, and in contrast to animal work18,45 and human antibiotic
intervention studies,10 vegan-donor FMTwas not able to reduce
(both native and d3-labeled) TMAO production in metabolic
syndrome patients, whereas autologous FMT was associated
with increased excretion of d3-TMAO. With regard to the latter,
the concomitant increase in A faecalis, which is known to
generate TMA,46 may provide some explanation for this
intriguing ﬁnding. Vegan-donor FMT led to a shift toward
vegan-like microbiota composition in some, but not all, recip-
ients. This could be related to the limited baseline fecal
microbiota differences and continuation of an omnivorous diet
after vegan-donor FMT, which together may have resulted in a
limited effect size of the FMT on TMAO conversion. We did not
choose to putmetabolic syndromepatients on a vegan diet after
vegan-donor FMT because we have previously reported meta-
bolic changes after a single donor FMT32 without a dietary
intervention,andthe introductionofastandardizeddiet isknown
to affect intestinal microbiota composition; this would include
bias.47 The heterogeneity in vegan-donor fecal microbiota
composition, as a consequence of using multiple vegan FMT
donors, might also have added to the variation in microbiota
changes seen following vegan-donor FMT.However,we recently
showed that the donor FMT effect on metabolism is largely
driven by the receiving patient rather than the donor.32 Albeit
modest and lower comparedwithmetabolic syndrome patients,
our vegandonors still hada residual capacity toconvert carnitine
to TMAO, which may explain that d6-TMA and d6-TMAO derived
from d6-choline remained almost absent in plasma and urine
after vegan-donor FMT. Moreover, we did not observe differ-
ences in FDG uptake at baseline between vegans andmetabolic
syndrome patients. This was surprising because previous trials
have reported on increased FDG uptake in metabolic syndrome
patients versus controls,48 anda vegandiet hasbeenassociated
with decreased inﬂammation and protection from metabolic
syndrome.49Vegan-donor FMTdidnot affect aorticwall 18F-FDG
uptake or ex vivo cytokine production, both surrogate param-
eters for an atherogenic proinﬂammatory state. The nonsignif-
icant changes in TMAO production on vegan FMT align with the
observations of Seldin et al showing a linear relation between
amountofTMAOonaortic vascularendothelial cell inﬂammation
in an animal model of CVD.50 In combination with this limited
TMAO-lowering potential of vegan-donor FMT, the timing of the
posttreatment measurements (2 weeks after FMT) might have
been too fast after intervention to observe a maximal effect on
TMAO production and PET/CT imaging. Nevertheless, FMT is
capable of (permanently) changing the gut microbiota from
2 weeks after intervention,22 and we previously showed signif-
icant reductions in PET/CT signal of the aortic wall in a similarly
short-term time window (between 3 days and 8 weeks) after
intervention.51,52
Our study has certain limitations. First, we assessed short-
term outcome of vegan-donor FMT in male obese west
European participants, possibly precluding generalization of
our ﬁndings to other patient groups and not studying long-term
outcome. Second, as a consequence of our randomized
controlled trial design and in combination with the intensive
study program for the participants, the sample size of our study
is small. We tried tominimize the risk for important type II errors
imposed by this small sample size by the use of sensitive (stable
isotope–based) outcome parameters that, in previous studies,
rendered signiﬁcant effect10,11; however, the large variation in
TMAO metabolism limits strong conclusions regarding part of
our hypotheses. Third, participants adhered to their own
omnivorous diet after intervention, which, in hindsight, could
have attenuated treatment-induced changes. Finally, dietary
records are notoriously inaccurate.53 Nevertheless, the main
strength of the present study is that we investigated the
relationship among intestinal microbiota, TMAO production,
and surrogate markers of vascular inﬂammation using feces
from participants with a longstanding vegan diet.
In conclusion, in this pilot study, single vegan-donor FMT
altered intestinal microbiota composition but was not able to
affect TMAO production or an atherogenic proinﬂammatory
state in patients with metabolic syndrome. The small
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(underpowered) sample size and short-term follow-up period
might have contributed to the lack of noticed effect. Because
lean-donor FMT can alter both fecalmicrobiota composition and
glucose metabolism in similarly size groups of metabolic
syndrome patients,5 our data underscore the need for time-
interval–dependent metabolic ﬂux studies in humans to study
reproducibility and validation of this mode of intervention in
cardiometabolic disease. Furthermore, the selection of donors
and recipients based on high versus low TMAO levels and
baseline fecal microbiota composition,32 and not simply
metabolic syndrome status, would have potentially larger
capabilityofmonitoring forchange inTMAOproductionpotential
in recipients of FMT in future studies. Consequently, further
studies disentangling the role of intestinal microbiota compo-
sition in TMAO production and CVD are recommended.19
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 Table S1. Safety parameters in obese metabolic syndrome subjects before and after FMT.  
 
Autologous 
FMT  t=0 
Autologous 
FMT  t=2w 
P-
value 
Vegan donor 
FMT t=0 
Vegan 
donor FMT 
t=2w 
P-
value 
Hemoglobin 
(mmol/l) 
9.6 ± 0.4 9.2 ± 0.5 0.01 9.5 ± 0.6 9.6 ± 0.6 0.54 
Thrombocytes 
(*10^9/l) 
229.1 ± 
20.8 
239.1 ± 
39.2 
0.23 
239.9 ± 
48.3 
243.2 ± 
56.9 
0.71 
Leucocytes (*10^9/l) 6.3 ± 1.2 6.0 ± 0.8 0.28 5.6 ± 1.2 5.6 ± 0.9 0.87 
CRP (mg/ml) 
 
1.9  
[1.2 – 
4.5] 
3.6  
[1.2 – 
5.1] 
0.59 
1.5  
[0.8 – 4.3] 
2.2  
[1.0 – 5.8] 
0.51 
Creatinine (umol/l) 
80.4 ± 
13.1 
81.4 ± 
14.0 
0.57 85.7 ± 10.7 85.0 ± 9.0 0.61 
Bilirubin (iU/l) 10.0 ± 4.5 10.1 ± 3.3 0.87 9.3 ± 2.1 9.5 ± 3.0 0.74 
ALT (iU/l) 
37.2 ± 
12.9 
29.4 ± 8.4 0.01 35.1 ± 8.4 
34.9 ± 
13.3 
0.93 
AST (iU/l) 
30.2 ± 
11.6 
24.1 ± 5.2 0.14 26.7 ± 5.4 
26.4 ± 
12.9 
0.92 
AP (iU/l) 
74.8 ± 
18.2 
71.0 ± 
16.5 
0.13 71.1 ± 17.1 
58.9 ± 
26.7 
0.19 
γGT (iU/l) 
44.2 ± 
26.5 
33.7 ± 
13.7  
0.08 49.8 ± 26.0 
46.9 ± 
34.9 
0.62 
Glucose (mmol/l) 6.18 ± 0.9 6.0 ± 0.6 0.61 5.8 ± 0.5 5.9 ± 0.6 0.62 
Insulin (miU/l) 
107.7 ± 
45.5 
121.0 ± 
76.5 
0.38 
146.0 ± 
63.7 
140.7 ± 
64.8 
0.78 
HbA1C (mmol/mol) 38.7 ± 3.6 38.3 ± 3.9 0.22 36.9 ± 5.1 37.4 ± 3.5 0.48 
Total cholesterol 
(mmol/l) 
5.3 ± 0.8 5.0 ± 0.7 0.04 5.3 ± 0.9 5.3 ± 0.9 0.94 
LDL-c (mmol/l) 3.1 ± 1.3 3.2 ± 0.5 0.68 3.5 ± 0.7 3.5 ± 0.8 0.85 
HDL-c (mmol/l) 1.2 ± 0.2 1.2 ± 0.2 0.78 1.1 ± 0.2 1.2 ± 0.2 0.47 
Triglycerides 
(mmol/l) 
1.3  
[1.1 – 
1.6] 
1.0  
[0.7 – 
1.5] 
0.005 
1.3  
[1.0 – 1.6] 
1.3  
[1.0 – 2.2] 
0.92 
Data are depicted as means + SDs or medians + IQRs, based on their distribution. A p-value < 0.05 
was considered significant. ALT = alanine transaminase; AP = alkaline phosphatase; AST = aspartate 
transaminase; CRP = c-reactive protein; FMT = fecal microbiota transplantation; γGT = gamma-
glutamyltransferase; HbA1c = glycated hemoglobin; HDL-c = high-density lipoprotein cholesterol; 
IQR = interquartile range; LDL-c = low-density lipoprotein cholesterol; SD = standard deviation  
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 Table S2. Daily nutritional intake in lean vegan donors and obese metabolic syndrome subjects. 
 
Metabolic syndrome 
patients 
All (n=19) 
Vegan donors 
(n=8) 
P-value 
Calories (kcal/day) 2038.7 ± 381.9 2068.3 ± 264.6 0.86 
Fat (g/day) 76.1 ± 16.3 72.8 ± 17.7 0.75 
Carbohydrates (g/day) 203.9 ± 70.0 245.0 ± 46.5 0.20 
Protein (g/day) 84.7 ± 16.5 69.2 ± 5.5 0.09 
Fiber (g/day) 18.0 ± 4.2 43.4 ± 19.2 <0.001 
 
Shown is daily dietary intake, divided in 5 food constituents, as calculated from a 7-day dietary record. 
Data are depicted as means + SDs. A p-value < 0.05 was considered significant 
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 Table S3. Daily nutritional intake of obese metabolic syndrome subjects before and after FMT. 
 
Autologous 
FMT  t=0 
Autologous 
FMT t=2w 
P-value 
Vegan 
donor 
FMT t=0 
Vegan 
donor 
FMT t=2w 
P-value 
Calories 
(kcal/day) 
1951.6 ± 
379.8 
1728.7 ± 
289.8 
0.13 
2010.4 ± 
343.2 
2128.6 ± 
499.1 
0.33 
Fat (g/day) 
72.7 ± 
13.7 
59.2 ± 7.6 0.13 
75.5 ± 
17.1 
74.3 ± 
18.2 
0.86 
Carbohydrates 
(g/day) 
178.3 ± 
56.1 
184.9 ± 
65.3 
0.53 
209.7 ± 
71.4 
218.8 ± 
94.6 
0.51 
Protein (g/day) 
89.2 ± 
19.4 
76.8 ± 
12.7 
0.11 78.2 ± 9.4 
82.1 ± 
13.1 
0.32 
Fiber (g/day) 17.4 ±5.9 18.1 ± 4.6 0.51 17.8 ± 3.2 
17.1 ± 
4.3 
0.56 
 
Shown is daily dietary intake, divided in 5 food constituents, as calculated from a 7-day dietary record. 
Data represent dietary recording of metabolic syndrome subjects, in the autologous and vegan FMT 
group, both before and after treatment.  Data are depicted as means + SDs. A p-value < 0.05 was 
considered significant. FMT = fecal microbiota transplantation 
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 Figure S1. D6-choline plasma and urine metabolites. 
 
 
 
 
 
 
 
 
 
 
 
Graphs showing the 24-hour appearance of d6-choline in plasma (A), the 24-hour appearance of d6-
TMAO (from d6-choline) in plasma (B) and the total urinary excretion of d6-TMAO and d6-TMA in 
the 24 hours following oral ingestion of 250mg d6-labeled choline (C-D). Data are depicted as box-
and-whisker plots. No significant differences were found. Auto FMT = autologous fecal microbiota 
transplantation; Donor FMT = lean vegan donor fecal microbiota transplantation; iAUC = incremental 
area under the curve; MetS = obese omnivorous metabolic syndrome patients; TMA = trimethylamine; 
TMAO = trimethylamine-N-oxide; Vegans = lean vegan FMT donors 
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 Figure S2A-D. Monocyte cytokine production after lean vegan donor or autologous FMT. 
Depicted is the ex vivo monocyte production of 4 different cytokines (A: IL1-β; B: IL6; C: IL10; D: 
TNF-α), after in total 6 stimuli of which RPMI served as the control stimulus. Data are depicted as 
box-and-whisker plots. A p-value < 0.05 was considered significant and is marked with an asterisk. 
Auto = autologous fecal microbiota transplantation; Allo = lean vegan donor fecal microbiota 
transplantation; e. coli = Escherichia coli; IL = interleukin; LPS = lipopolysaccharide; oxLDL = 
oxidized low=density lipoprotein; RPMI = Roswell Park Memorial Institute medium: TNFα = tumor-
necrosis factor α 
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